Why the study?
Despite clinical trials on pharmacologic treatment of cardiogenic shock, an established and widely accepted decision-making algorithm on the use of inotropic agents is lacking.
How should inotropic agents and vasopressors be used in the management of cardiogenic shock?
How should inotropic agents and vasopressors be used in the management of cardiogenic shock?
This review provides a proposed decision-making algorithm for the initial management of cardiogenic shock using inotropes and vasopressors.
Proposed stage-based algorithm may guide initial inotrope-vasopressor selection in cardiogenic shock; leaves open need for prospective validation.
PURPOSE OF REVIEW: Cardiogenic shock is a multifactorial and diverse entity in which inotropes are the cornerstone therapy. Although published clinical trials have focused on pharmacologic treatment of cardiogenic shock, there is lack of an established and widely accepted decision-making algorithm on the use of inotropic agents in cardiogenic shock. RECENT FINDINGS: The current review incorporates cardiogenic shock pathophysiology, inotropes and vasopressors pharmacodynamics. It emphasizes on each agent's indications, potential adverse effects, highlights special considerations and fsummarizes the recent guidelines. SUMMARY: Finally, proposes an algorithm of inotropes and vasopressors use and their potential combinations based on the clinical stage of cardiogenic shock. This algorithm can be used as a guide during the initial management of cardiogenic shock while underlying cause investigation is underway.
No takes yet. Share an insight, caveat, or question.
Polyzogopoulou et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: